Search This Blog

Wednesday, September 21, 2022

Pacira: Positive Topline Data from Phase 3 Study of EXPAREL

 -- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours --

-- Company on track to submit supplemental New Drug Application in first quarter of 2023 --

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.